Jones Financial Companies Lllp Boosts Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Jones Financial Companies Lllp raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 2,750.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114 shares of the company’s stock after buying an additional 110 shares during the quarter. Jones Financial Companies Lllp’s holdings in Medpace were worth $38,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. R Squared Ltd purchased a new stake in shares of Medpace during the 4th quarter worth about $30,000. Stone House Investment Management LLC purchased a new stake in shares of Medpace during the 3rd quarter worth about $33,000. True Wealth Design LLC grew its holdings in shares of Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares during the period. Arcadia Investment Management Corp MI purchased a new stake in shares of Medpace during the 4th quarter worth about $72,000. Finally, Venturi Wealth Management LLC grew its holdings in shares of Medpace by 602.0% during the 4th quarter. Venturi Wealth Management LLC now owns 344 shares of the company’s stock worth $114,000 after purchasing an additional 295 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 1.0 %

NASDAQ MEDP opened at $322.93 on Wednesday. The stock has a market cap of $9.84 billion, a PE ratio of 25.57, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The business has a 50 day moving average price of $339.49 and a two-hundred day moving average price of $340.34.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Robert W. Baird boosted their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Medpace presently has an average rating of “Hold” and an average price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.